Redefining intensive LDL-c management in high CV risk patients - The case for combination therapy
Meeting report with videos, slides and e-learning of a PACE-CME symposium during the ESC Congress 2021.
1-3 of 3
- Redefining intensive LDL-c management in high CV risk patients - The case for combination therapyExpanding therapeutic options for LDL-c lowering
Christie Ballantyne, MD
- Redefining intensive LDL-c management in high CV risk patients - The case for combination therapyCombination therapy with PCSK9 mAbs in post-MI patients
Derek Connolly, MD, PhD
- Redefining intensive LDL-c management in high CV risk patients - The case for combination therapyChanging the paradigm on LDL-c-lowering in high CV risk patients
Prof Kausik Ray
